PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2016

Conditions
Diffuse Intrinsic Pontine GliomaProgressive or Refractory High-Grade Glioma
Interventions
DRUG

Crenolanib

Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

Sponsors
All Listed Sponsors
collaborator

Arog Pharmaceuticals, Inc.

INDUSTRY

collaborator

The V Foundation for Cancer Research

OTHER

lead

St. Jude Children's Research Hospital

OTHER